Standout Papers
Citation Impact
Citing Papers
Complement and microglia mediate early synapse loss in Alzheimer mouse models
2016 StandoutScience
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
2010 StandoutScience
Infection, inflammation, height, and longevity
2005 Standout
Recognition of the amyloid precursor protein by human γ-secretase
2019 Science
Complement Factor H Polymorphism and Age-Related Macular Degeneration
2005 StandoutScience
Exercise training increases size of hippocampus and improves memory
2011 Standout
Sleep Drives Metabolite Clearance from the Adult Brain
2013 StandoutScience
Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
2011
Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
2019 StandoutNobel
Plasma β-amyloid in Alzheimer’s disease and vascular disease
2016 StandoutNobel
Stability of person-specific blood-based infrared molecular fingerprints opens up prospects for health monitoring
2021 StandoutNobel
Aβ-induced vulnerability propagates via the brain’s default mode network
2019
Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575
2009
Involvement of Human Blood Arylesterases and Liver Microsomal Carboxylesterases in Nafamostat Hydrolysis
2006
Thiazolidinediones
2004 Standout
Osteoporosis
2019 Standout
The Amyloid-β Pathway in Alzheimer’s Disease
2021
Targeting Aβ and tau in Alzheimer's disease, an early interim report
2009
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
2011 Standout
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
2009
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
2010
Plasma phospholipids identify antecedent memory impairment in older adults
2014
Vascular dementia
2015 Standout
An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease
2011
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
2018 NatureNobel
Sex differences in Alzheimer disease — the gateway to precision medicine
2018
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
2013
Alzheimer's disease
2011 Standout
Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition
2011
Mild Cognitive Impairment
2011 Standout
Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas
2004 StandoutNobel
Detection of early gene expression changes by differential display in the livers of mice exposed to dichloroacetic acid
2001
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease
2010
Inflammatory Biomarkers, Hormone Replacement Therapy, and Incident Coronary Heart Disease
2002
A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder
2014
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
2002 Standout
Alzheimer disease therapy—moving from amyloid-β to tau
2013
The Cellular Phase of Alzheimer’s Disease
2016
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
2019 Standout
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
2013 Standout
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
2009 Standout
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
2010
Chemoenzymatic synthesis of (S)-duloxetine using carbonyl reductase from Rhodosporidium toruloides
2016
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
2009
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
2010
Regional brain hypometabolism is unrelated to regional amyloid plaque burden
2015
Dynamic Analysis of Amyloid β-Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal Aβ during Age-Related Plaque Formation
2011
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
2004 Standout
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
2013 Standout
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease
2009
Alzheimer's disease: progress in prediction
2009
The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor
2013
Alzheimer's disease
2006 Standout
Alzheimer's disease
2016 Standout
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
2011
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
2006
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease
2015
In vitrostability and metabolism of salvinorin A in rat plasma
2009
Antibody Therapeutics Targeting Aβ and Tau
2017
Human Carboxylesterase Isozymes: Catalytic Properties and Rational Drug Design
2006
Lessons from a Failed γ-Secretase Alzheimer Trial
2014
Biomarker Modeling of Alzheimer’s Disease
2013
Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>
2009
Mild Cognitive Impairment
2009
Alzheimer's Disease
2010 Standout
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
2014
Alzheimer's disease: clinical trials and drug development
2010
Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease
2012
Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1‐42
2010
The Amyloid State of Proteins in Human Diseases
2012 Standout
Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606
2017
Concentration-Dependent Modulation of Amyloid-β in Vivo and in Vitro Using the γ-Secretase Inhibitor, LY-450139
2006
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases
2012
Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease
2011
Soluble Aβ Oligomers Are Rapidly Sequestered from Brain ISF In Vivo and Bind GM1 Ganglioside on Cellular Membranes
2014
Amyloid biomarkers in Alzheimer's disease
2015
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
2014
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
2006
Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease
2009
Evidence for Ordering of Alzheimer Disease Biomarkers
2011
The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model
2016
Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
2011
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
2009
Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following γ-Secretase Inhibition
2008
The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort
2010
The road to restoring neural circuits for the treatment of Alzheimer's disease
2016 Nature
Ecology of the Aging Human Brain
2011
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
2017 Standout
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
2003
Single-cell transcriptomic analysis of Alzheimer’s disease
2019 StandoutNature
A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system
2009
A Sensitive Aβ Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid
2014
The Dynamics of Cortical and Hippocampal Atrophy in Alzheimer Disease
2011
γ-Secretase and its modulators: Twenty years and beyond
2019
Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?
2011
The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease
2012
Intramembrane Proteolysis
2009
Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimer’s Disease
2016
Comparing predictors of conversion and decline in mild cognitive impairment
2010
Markers of Inflammation and Cardiovascular Disease
2003 Standout
Lecanemab in Early Alzheimer’s Disease
2022 Standout
Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia
2012
Relationships between biomarkers in aging and dementia
2009
Nanozymes: Classification, Catalytic Mechanisms, Activity Regulation, and Applications
2019 Standout
Combined Plasma Biomarkers for Diagnosing Mild Cognition Impairment and Alzheimer’s Disease
2013
Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance
2011
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
2014
Regioselective Synthesis of 3-Benzazepinones and Unexpected 5-Bromo-3-benzazepinones
2010
Determining clinically meaningful decline in preclinical Alzheimer disease
2019
Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnestic MCI
2019
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
THE MAMMALIAN CARBOXYLESTERASES: From Molecules to Functions
1998
New ELISAs with high specificity for soluble oligomers of amyloid β‐protein detect natural Aβ oligomers in human brain but not CSF
2013
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia
2019
The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease
2013 Standout
Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42
2014
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
2011 Standout
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)
2018 Standout
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
2011 Standout
Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease
2006
Tau is reduced in AD plasma and validation of employed ELISA methods.
2012
Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid β-peptides in human cerebrospinal fluid
2011
Inflammation in Cardiovascular Disease
2002
MRI and CSF biomarkers in normal, MCI, and AD subjects
2009
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study
2016
Applications of targeted proteomics in systems biology and translational medicine
2015
MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults
2011
Confined acids catalyze asymmetric single aldolizations of acetaldehyde enolates
2018 StandoutScienceNobel
Sex modifies the APOE‐related risk of developing Alzheimer disease
2014
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
2014
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease
2006
Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
2018
Plasma tau in Alzheimer disease
2016 StandoutNobel
Carboxylesterases: structure, function and polymorphism in mammals
2010
Role of C-Reactive Protein in Cardiovascular Disease
2003
Amyloid precursor protein (APP) traffics from the cell surface via endosomes for amyloid β (Aβ) production in the trans -Golgi network
2012 StandoutNobel
A Candidate Plasma Protein Classifier to Identify Alzheimer's Disease
2014
Brain β-amyloid load approaches a plateau
2013
Gold-Catalyzed Carbon−Heteroatom Bond-Forming Reactions
2011 Standout
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
Molecular Origin of Blood‐Based Infrared Spectroscopic Fingerprints**
2021 StandoutNobel
Discrimination Analysis of Blood Plasma Associated with Alzheimer's Disease Using Vibrational Spectroscopy
2013
Effect of 1 Night of Total Sleep Deprivation on Cerebrospinal Fluid β-Amyloid 42 in Healthy Middle-Aged Men
2014
Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
2014
Donanemab in Early Alzheimer’s Disease
2021
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
2019
Real-Time Bioluminescence Imaging of Glycans on Live Cells
2010 StandoutNobel
Chemical Glycoproteomics
2016 StandoutNobel
Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas
2004 StandoutNobel
The future of blood‐based biomarkers for Alzheimer's disease
2013
APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern
2015
Works of Robert A. Dean being referenced
Pharmacokinetics and Pharmacodynamics of Edivoxetine (LY2216684), a Norepinephrine Reuptake Inhibitor, in Pediatric Patients with Attention-Deficit/ Hyperactivity Disorder
2012
Revisiting the framework of the National Institute on Aging‐Alzheimer's Association diagnostic criteria
2013
A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease
2010
Quantitative analysis of amyloid β peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry
2006
Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease
2010
An Enzyme-Generated Fragment of Tau Measured in Serum Shows an Inverse Correlation to Cognitive Function
2013
Purification and Cloning of a Broad Substrate Specificity Human Liver Carboxylesterase That Catalyzes the Hydrolysis of Cocaine and Heroin
1997
Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-β After Inhibition of γ-Secretase
2007
Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease
2009
Effects of Duloxetine on Norepinephrine and Serotonin Transporter Activity in Healthy Subjects
2013
Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women
2001
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
2011
β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage
2014
Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease
2008
Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid β Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease
2011
Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine
1994
Safety, Tolerability, and Changes in Amyloid β Concentrations After Administration of a γ-Secretase Inhibitor in Volunteers
2005
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
2009 Standout
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease
2012
Validation of a Multiplex Assay for Simultaneous Quantification of Amyloid-β Peptide Species in Human Plasma with Utility for Measurements in Studies of Alzheimer's Disease Therapeutics
2012
P3‐093: Characterization of CSF Aβ1–42, Tau and p‐Tau181p concentrations at baseline in Alzheimer's disease neuroimaging initiative study patients
2008
P4‐346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease
2008
Validation of Assays for Measurement of Amyloid-β Peptides in Cerebrospinal Fluid and Plasma Specimens from Patients with Alzheimer's Disease Treated with Solanezumab
2013
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects
2010
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
2015
Human liver cocaine esterases: ethanol‐mediated formation of ethylcocaine
1991
P3‐359: Central BACE1 inhibition by LY2886721 produces opposing effects on APP processing as reflected by cerebrospinal fluid sAPPalpha and sAPPbeta
2012
Amyloid-β1-15/16 as a Marker for γ-Secretase Inhibition in Alzheimer's Disease
2012
Revolutionizing Alzheimer's disease and clinical trials through biomarkers
2015
O4‐08‐06: SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F‐18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β‐AMYLOID PLAQUE‐SPECIFIC ANTIBODY, IN ALZHEIMER’S DISEASE (AD)
2016
P4-333 Safety, tolerability, and changes in plasma and cerebrospinal fluid amyloid beta concentrations after administration of a functional gamma-secretase inhibitor in healthy volunteers
2004
The Effects of Hormone Replacement Therapy and Raloxifene on C-Reactive Protein and Homocysteine in Healthy Postmenopausal Women: A Randomized, Controlled Trial1
2000
Validation of ELISA Methods for Quantification of Total Tau and Phosphorylated-Tau 181 in Human Cerebrospinal Fluid with Measurement in Specimens from Two Alzheimer's Disease Studies
2011
P3‐363: BACE inhibitor LY2886721 safety and central and peripheral PK and PD in healthy subjects (HSs)
2012